Altera�(ALTR)'s performance has been weak as shares are down almost 9% so far this year as compared to peers such as Xilinx (XLNX) and Lattice Semiconductor.
These three companies make programmable chips that can be bought by customers and then programmed according to their needs. But Xilinx and Lattice seems to be making all the right moves.
Not a Rosy Picture
Last month, Goldman Sachs downgraded Altera�� rating from "conviction buy" to "buy" owing to a belief that Altera could face some short-term weakness. Further, Altera�� quarterly report was not robust either. Revenue lowered 10% from the year-ago period and earnings dropped 24%. The company released the guidance for revenue of around $441 million at the mid-point, which was far behind the $473.66 million expectation.
Therefore, it seems like it�� all unstable conditions for Altera currently. However, patient investors might be interested in Altera with the stock trading pretty close to its 52-week low and being the cheapest among the three at 22 times earnings. The long-term prospects are not that bad, and taking into account the fact that Altera offers a dividend yield of 1.90%, it could be a good buy over the long run.
Hot Shipping Companies To Buy For 2015: Rosetta Resources Inc.(ROSE)
Rosetta Resources Inc., an independent exploration and production company, engages in the acquisition, exploration, development, and production of onshore oil and gas resources in the United States. It owns producing and non-producing oil and gas properties located primarily in South Texas, including the Eagle Ford, and in the Southern Alberta Basin in Northwest Montana. As of December 31, 2011, the company had an estimated 965 billion cubic feet equivalent of proved reserves, including 36,370 million barrels of oil, 50,219 million barrels of natural gas liquids, and 446 billion cubic feet of natural gas, as well as drilled 53 net wells. Rosetta Resources Inc. was incorporated in 2005 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Monica Wolfe]
Rosetta Resources (ROSE)
FPA Capital's largest holding is in Rosetta Resources. Here the guru holds on to a total of 1,419,402 shares of the company�� stock which makes up for 9.7% of its total portfolio and 2.32% of the company�� shares outstanding.
- [By Tyler Crowe]
Who's doing it the best?
Company % Liquids in�Portfolio Oil Production Replacement Rate (3 Years) Reserve Replacement Costs (3-Year Average) Per boe Rosetta Resources� (NASDAQ: ROSE ) 57% 846% $6.99 Continental Resources� (NYSE: CLR ) 72% 827% $12.61 Laredo Petroleum� (NYSE: LPI ) 52% 1,042% $13.51 SM Energy� (NYSE: SM ) 53% 392% $14.67 SandRidge Energy� (NYSE: SD ) 58% 704% $14.85
It can be pretty handy to evaluate the entire industry on how efficiently it's replacing reserves, but reserve replacement costs can be more effective in evaluating individual companies. The lower the costs, the better it is. According to Ernst & Young, the most effective company at controlling reserve replacement costs is private company�Antero Resources, with a three-year average reserve replacement cost of about $2.88 per barrel of oil equivalent. Antero, and four of the other top five companies on Ernst & Young's list, are almost pure natural gas plays. If we've learned one thing over the past couple of years, it's that oil reserves and natural gas reserves are two totally different things when it comes to value. The five following companies have more than 50% liquids on�their�reserves and had the lowest reserve replacement costs for 2012.Sources: Ernst & Young and S&P Capital IQ; author's calculations.
- [By Value Digger]
It is clear that these key metrics match the metrics of a heavily natural gas weighted company that also carries significant debt. To prove this, let's check out Comstock Resources (CRK). Comstock sold some assets recently to Rosetta Resources (ROSE) to reduce its long term debt which still remains high though.
- [By Vera Yuan]
��il and gas exploration and production company Rosetta Resources, Inc. (ROSE) rose in anticipation of an ease in regulations on the exportation of condensate, an ultra-light oil that undergoes minimal processing. This could allow the condensate to be exported at higher prices, alleviating a potential condensate glut in the U.S. and benefitting Rosetta.
10 Best Cheapest Stocks To Own For 2014: Omeros Corporation(OMER)
Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company?s lead PharmacoSurgery product candidates include OMS103HP, a Phase 3 clinical program evaluated for OMS103HP?s safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery, and arthroscopic anterior cruciate ligament; OMS302, a Phase 2b clinical trial completed product candidate for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201, a Phase 1/Phase 2 clinical trial completed program for use durin g urological surgery. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The company?s pipeline of preclinical product development programs includes Plasmin for Surgical and traumatic bleeding; PDE7 for addictions and compulsive disorders, and movement disorders; MASP-2 for macular degeneration, ischemia-reperfusion injury, transplant surgery, and radiation injury; and PDE10 for Schizophrenia. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.
Advisors' Opinion:- [By Monica Gerson]
Omeros (NASDAQ: OMER) shares fell 2.80% to $8.32 in the pre-market trading. Omeros shares have dropped 9.80% over the past 52 weeks, while the S&P 500 index has gained 16.18% in the same period.
- [By John Udovich]
Last week had been a busy week for biotech IPOs and follow-on offerings plus news from small cap biotech stocks like Omeros Corporation (NASDAQ: OMER), Argos Therapeutics Inc (NASDAQ: ARGS), Revance Therapeutics Inc (NASDAQ: RVNC) and TNI BioTech (OTCMKTS: TNIB) that�� worth noting as a new trading week begins:�
- [By John Udovich]
Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.
- [By John Udovich]
The biotech sector has been hot this year with�small cap biotech stocks�Fate Therapeutics Inc (NASDAQ: FATE),�Omeros Corporation(NASDAQ: OMER) and TNI BioTech (OTCMKTS: TNIB) being among those biotech stocks in the news this week. However, there has also been talk�and perhaps�some signs of a bubble in biotech that investors and traders alike need to consider. With that in mind, here is a recap of the latest news for biotech or small cap biotech stocks:
10 Best Cheapest Stocks To Own For 2014: Customers Bancorp Inc (CUBI)
Customers Bancorp, Inc. (Customers Bancorp), incorporated in April 2010, through its wholly owned subsidiary Customers Bank (the Bank), provides financial products and services to small businesses, not-for-profits and consumers through its fourteen branches in Southeastern Pennsylvania (Bucks, Berks, Chester and Delaware Counties), Rye, New York (Westchester County) and Hamilton, New Jersey (Mercer County). Customers Bank also provides liquidity to the mortgage market worldwide through the operation of its mortgage warehouse business. As of December 31, 2011, Customers Bancorp had total assets of $2.08 billion, including net loans (including held for sale loans) of $1.50 billion, total deposits of $1.58 billion. The Company offers a range of banking products and financial services to its commercial and consumer customers in Suburban Philadelphia, Pennsylvania, Central New Jersey and Southeastern New York. It offers a range of lending products to cater to its customers��needs, including small business loans, mortgage warehouse loans, multi-family and commercial real estate loans, residential mortgage loans and consumer loans. It also offers traditional depository products, including commercial and consumer checking accounts, non-interest-bearing demand accounts, money market deposit accounts, savings accounts and time deposit accounts and cash management services. On September 17, 2011, Customers Bank became a wholly owned subsidiary of Customers Bancorp. On September 17, 2011, Customers Bancorp acquired Berkshire Bancorp, Inc. and its subsidiary Berkshire Bank. In May 2013, Customers Bancorp Inc merged with CMS Bancorp Inc.
Lending Activities
The Company focuses its lending efforts to the lending areas, such as commercial lending, which includes business, small business and multi-family and commercial real estate lending; specialty Lending, which include warehouse lending, and consumer lending, which include local market mortgage lending and home equity lending. It also pr! ovide warehouse financing worldwide and multi-family lending in the Mid-Atlantic States.
The Bank�� commercial lending is segmented into three groups, which include multi-family and commercial real estate, business banking and small business banking. The small business banking platform originates loans, including small business administration loans, through the branch network sales force and a team of dedicated small business relationship managers. During the year ended December 31, 2011, it originated and closed $121.5 million of multi-family loans commitments. As of December 31, 2011, it had $536.9 million in commercial loans outstanding, comprising approximately 35.3% of its total loan portfolio (which includes loans held for sale). During 2011, it originated and closed $167.7 million of commercial loans and commitments. As of December 31, 2011, loans in its warehouse lending portfolio, as well as loans held for sale totaled $794.3 million outstanding, comprising approximately 52.3% of its total loan portfolio (which includes loans held for sale). During the year ended December 31, 2011, it funded $7.7 billion of mortgage loans under warehouse facilities.
The Company offers a range of deposit products to its customers, including checking accounts, savings accounts, money market accounts and other deposit accounts, including fixed-rate, fixed-maturity retail time deposits ranging in terms from 30 days to five years, individual retirement accounts, and non-retail time deposits consisting of jumbo certificates greater than or equal to $100,000. As of December 31, 2011, its deposit portfolio was consisted of 54.9% of core deposits. Its financial products include Internet banking, wire transfers, electronic bill payment, lock box services, remote deposit capture services, courier services, merchant processing services, cash vault, controlled disbursements, positive pay and cash management services (including account reconciliation, collections and sweep accounts).
! Sources o! f Fund
The Company offers a range of deposit accounts, including checking, savings, money market and time deposits. Deposits are obtained primarily from its service area. As of December 31, 2011, the total deposits grew to $1.58 billion.
Investment Activities
The Company�� investment securities portfolio consists of United States Treasury, government agency and mortgage-backed securities (guaranteed by an agency of the United States government and non-agency guaranteed), municipal securities, domestic corporate debt, and asset-backed securities. In addition to generating revenue, it maintains the investment portfolio to manage interest rate risk, provide liquidity, provide collateral for other borrowings and diversify the credit risk of earning assets. As of December 31, 2011, $79.1 million of its investment securities were classified as available for sale (AFS). As of December 31, 2011, the fair value of its investment securities portfolio was approximately $409.9 million. As of December 31, 2011, it held $319.5 million of investment securities that were classified as held to maturity (HTM).
Advisors' Opinion:- [By Rich Smith]
Wyomissing, Pa.-based Customers Bancorp (NASDAQ: CUBI ) has a new CFO.
On Tuesday, Customers Bancorp announced that Interim Chief Financial Officer James D. Hogan�intends to retire from the bank on Aug. 13. Replacing Hogan will be Robert E. Wahlman, a new hire from Doral Financial, who will join Customers initially in the post of executive vice president on Aug. 5, and then be promoted to permanent CFO on the 13th.
10 Best Cheapest Stocks To Own For 2014: Landec Corporation(LNDC)
Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells polymer products for food and agricultural products, medical devices products, and licensed partner applications incorporating its patented polymer technologies. It has two polymer technology platforms that include Intelimer polymers, a proprietary class of crystalline, hydrophobic polymers, which respond to temperature changes in a controllable, predictable way; and Hyaluronan Biopolymer, a non-crystalline, hydrophilic polymer that exists naturally within the human body. The company?s Food Products Technology segment markets and packs produced and specialty packaged whole and fresh-cut vegetables utilizing the proprietary BreatheWay specialty packaging technology for the retail grocery, club store, and food services industry. This segment also sells BreatheWay packaging to partners for non-vegetable products. Its Food Export segment purchases and sells primarily whole commodity fruit and vegetable products to Asian markets. The company?s Hyaluronan-based Biomaterials segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is primarily distributed in the extracellar matrix of connective tissues in both animals and humans for medical use primarily in the ophthalmic, orthopedic, and veterinary markets. It also supplies hyaluronan to customers pursuing other medical applications, such as aesthetic surgery, medical device coatings, tissue engineering, and pharmaceuticals. Its Technology Licensing segment licenses Intellicoat, a proprietary seed coating technology to the farming industry; and Intelimer polymers for personal care products and other industrial products. The company sells its products in the United States, Canada, Taiwan, Belgium, Indonesia, China, and Japan. Landec Corporation was founded in 1986 and is based in Menlo Park, California.
Advisors' Opinion:- [By Lauren Pollock]
Landec Corp.'s(LNDC) fiscal first-quarter profit grew 8.8% as the food-packaging maker reported higher revenue due to strong demand for vegetables. Margins, however, fell due to an increase in lower-margin food service sales and higher-than-expected raw produce costs.
- [By Laura Brodbeck]
Thursday
Earnings Expected From: Landec Corporation (NASDAQ: LNDC), Resources Connection, Inc. (NASDAQ: RECN) Economic Releases Expected: Indian manufacturing PMI, Spanish manufacturing PMI, Hong Kong retail sales, Italian manufacturing PMI, French manufacturing PMI, German manufacturing PMI, eurozone manufacturing PMI, US manufacturing PMI, Canadian manufacturing PMI, US manufacturing PMIFriday
10 Best Cheapest Stocks To Own For 2014: Equity One Inc. (EQY)
Equity One, Inc., a real estate investment trust (REIT), engages in the ownership, management, acquisition, renovation, and development of neighborhood and community shopping centers in the United States. Its shopping centers are anchored by supermarkets, drug stores, or discount retail store chains. As of December 31, 2006, the company?s property portfolio consisted of 179 properties, including 166 shopping centers, 6 development parcels, and 7 non-retail properties. As a REIT, Equity One would not be subject to federal tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1992 and is based in North Miami Beach, Florida with an additional office in Israel.
Advisors' Opinion:- [By Dividend King]
Equity One Inc. (EQY): Equity One Inc. is trading just under its 52-week high of $20.27. The stock issues an annual dividend of $0.88, has a yield of 4.40% and a payout ratio of 142%.
10 Best Cheapest Stocks To Own For 2014: Peregrine Pharmaceuticals Inc.(PPHM)
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of monoclonal antibodies for the treatment of cancer and viral infections. Its products under development include bavituximab, a phosphatidylserine-targeting antibody, which is in Phase II trials for the treatment of front-line and second-line non-small cell lung cancer (NSCLC), and pancreatic cancer; and Cotara, a DNA/histone-targeting antibody that is in Phase II trial for the treatment of recurrent glioblastoma multiforme. The company is also developing bavituximab in combination with ribavirin, which is in Phase II clinical trial for the treatment of patients with genotype-1 hepatitis C virus infection. In addition, it has investigator-sponsored trial programs that evaluate bavituximab for the treatment of patients with liver cancer, second-line castration resistant prostate cancer, HER-2 negative metastatic breast cancer, and locally advanced or metasta tic NSCLC. Further, the company, through its wholly-owned subsidiary, Avid Bioservices, Inc., provides integrated current Good Manufacturing Practices (cGMP) commercial and clinical manufacturing services in the United States, including contract manufacturing of antibodies, recombinant proteins, and enzymes; cell culture development; process development; and testing of biologics for biopharmaceutical and biotechnology companies under cGMP. It has licensing agreements with the University of Texas Southwestern Medical Center; Merck KGaA; SuperGen, Inc.; and Affitech A/S. Peregrine Pharmaceuticals, Inc. intends to sell its products in the United States and internationally in collaboration with marketing partners or through a direct sales force. The company was founded in 1981 and is based in Tustin, California.
Advisors' Opinion:- [By Rick Munarriz]
I went out on a limb last week, and now it's time to see how that decision played out.
I predicted that Noodles & Co. (NASDAQ: NDLS ) would close lower on the week. After seeing the fresh IPO more than double and command a $1.3 billion market cap far sooner than its fundamentals should allow, I figured it would be in for reality check. A negative Barron's piece kicked off the week in the seemingly appropriate bearish tone, but the shares did start to claw their way back later in the week. It wasn't enough. The shares fell 3% on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI ) . This has been a tricky call lately, so how did it play out this time? Well, the market closed nicely higher this week. The Nasdaq moved 3.5% higher, and the Dow managed to close just 2.2% higher. I was right. My final call was for Peregrine Pharmaceuticals (NASDAQ: PPHM ) to beat Wall Street's income estimates in its latest quarter. The upstart biotech tackling cancer through monoclonal antibodies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a loss of $0.06 a share during the quarter, and it came through with exactly that. It wasn't a beat, though, so I was wrong.Two out of three? I can do better than that.
10 Best Cheapest Stocks To Own For 2014: Emak SpA (EM)
Emak SpA is an Italy-based company primarily engaged in the manufacture of outdoor power equipment for gardening, forestry, agriculture and industry. The Company�� portfolio includes chainsaws, brush cutters, lawnmowers, garden tractors, water pumps, high pressure washers, transporters, rotary cultivators, motor hoes and power cutters, among others. It also manufactures spare parts, accessories and protective clothing. The Company sells its products under various brand names, such as Oleo-Mac, Efco, Bertolini, Nibbi and Staub. Emak SpA directly manages distribution in the Italian market and it sells products, through its commercial subsidiaries, in France, Germany, the United Kingdom, Spain, the countries of Benelux, Poland, Ukraine, among others.The Company is controlled by Yama SpA, which is an industrial holding company. Advisors' Opinion:- [By Holly LaFon]
As true value investors, Brandes oft en moves against the crowd amid markets' constantly changing performance cycles. Take the recent equity market weakness in a number of emerging market (EM) countries for example. Over the last year, while macroeconomic and geopolitical concerns cast a cloud of uncertainty over the asset class in general, we started to see some interesting investment opportunities at the company level as a result of such market weakness.
- [By Canadian Value]
For 20+ years there has been a coherent growth story around Emerging Markets (EM), where the label "Emerging Market" had real meaning within a common knowledge perspective. Today ��not so much. Today the story is that it was easy money from the Fed that drove global growth, EM or otherwise. Today the story is that Emerging Markets are just the levered beneficiaries or victims of Fed monetary policy, no different than anyone else��
- [By Federico Zaldua]
Brookfield Infrastructure has a number of potentially profitable areas for investment around the world but, above all, in infrastructure hungry Emerging Markets (EM) such as Brazil. According to Credit Suisse analysts, in Brazil, funds can be invested at Funds From Operations (FFO) yields above 12%. Therefore, the company's ability to grow its distribution yield, whether through acquisitions or organically, is critical to evaluate the company's value. Moreover, the currently conservative dividend payout ratio should allow Brookfield Infrastructure to self-finance on going opportunities.
No comments:
Post a Comment